Post on 05-Sep-2020
2016 Pharmacy Education Series
November 16, 2016Pharmacy Pearls 2016
Today’s Presenters
Margaret Babin, RPh
Margaret Babin is a Pharmacy Clinical Coordinator at Tomball Regional Medical Center (TRMC) since November 2004 and has worked at TRMC since 2003. She has earned her Society of Infectious Diseases Pharmacists (SIDP) training certificate in Antimicrobial Stewardship in October 2016. She completed a Bachelor of Science in Pharmacy at the University of Houston in 1980. She is also preceptor for students completing introductory and advanced practice experiential education rotations with Texas A&M, Creighton, and Lake Erie College of Osteopathic Medicine (LECOM). Margaret is a member of the Houston Infectious Disease Network (HIDN) and the American Society of Hospital Pharmacists (ASHP). She is a contributing author in an upcoming article “Significant publications on infectious diseases pharmacotherapy in 2015” to be published in the American Journal of Hospital Pharmacy (AJHP).
Robley E Bartholomew, PharmD
Dr. Robley Bartholomew completed his Pharm.D. training at the Lake Erie College of Osteopathic Medicine College of Pharmacy in Bradenton, Florida. Upon completion of his Pharm.D. degree, Robley went on onto complete a PGY‐1 Pharmacy Residency at Bayfront Health, a level 2 trauma center in St. Petersburg, FL. Robley is currently training as a PGY‐2 Pharmacy Administration Resident at Community Health Systems in Franklin TN and will be completing this training in June 2017.
James M. Bunch PharmD, BCPS
James Bunch is currently the Director of the Clinical Pharmacy for Mat‐Su Regional Medical Center in Palmer, Alaska. He received his Doctor of Pharmacy degree from Idaho State University in 2005. Since then he spent 3 years serving the Native Alaskan Yupik tribe in Western Alaska by working for the Yukon Health Corporation as an inpatient pharmacist. He has spent the last nine years working in the Mat‐Su Valley where his duties have ranged from staff pharmacist, to clinical coordinator, assistant pharmacy director, and now director of pharmacy. In 2012 he became a board certified pharmacotherapy specialist. In the clinical world his interests lie in critical care and infectious disease.
Jo Ann S. Gibbs, PharmD, BCPS
Dr. Gibbs has been the Director of Pharmacy at Byrd Regional Hospital in Leesville, LA for 8 years. She is sharing a process developed for her facility to keep track of all the paperwork involved in controlled substance auditing. This process has worked well and made our tracking and investigations more meaningful.
Sue V. Ie, PharmD
Sue received her Doctorate of Pharmacy from Touro University California College of Pharmacy. She is currently a postdoctoral fellow in health information and clinical outcomes for Community Health Systems and Wolters Kluwer Health. She is an active member of the American College of Clinical Pharmacy and is pursuing quality improvement and clinical outcomes research. Sue is a strong proponent of utilizing health information technology to streamline clinical workflows and drive clinical initiatives.
George E. Jossell, PharmD
Currently, director of pharmacy services at Lea Regional Medical Center, Dr. Jossell has practiced pharmacy at the management level for 21 years. Graduating from the University of Minnesota School of Pharmacy in 1976, he began his career in retail pharmacy culminating with 6 years as a retail pharmacy manager. Dr. Jossell transitioned to hospital pharmacy practice at Mount Sinai Hospital of Chicago, Illinois, a 400 bed, level 1 acute care center where he served as a decentralized pharmacist in the cardiac critical care unit before becoming assistant director of pharmacy. In this role, as automation project manager, he supervised the automation of the Mount Sinai pharmacy with pick to light medication carousels, remote checking of sterile compounding and a high speed medication re‐packager, to complement AcuDose automated dispensing machines and Narc‐station. Four years later he assumed the role of director of pharmacy at Roseland Hospital in Chicago for two years before accepting his current role at Lea Regional for the past two years. Dr. Jossell is a recent graduate of University of Florida School of Pharmacy where he completed a three year PharmD course, graduating in August, 2016.
Michael Kleinschmidt, PharmD, BCPS
Michael Kleinschmidt is presently the Director of Pharmacy at Brandywine Hospital in Coatesville, Pennsylvania. He is a graduate of the Philadelphia College of Pharmacy, and a Board Certified Pharmacotherapy Specialist. During his tenure as a pharmacist, he has worked in a variety of arenas as a clinical pharmacist, from the ED to General Medicine to Neuro‐Trauma. For the last 2 years, Dr. Kleinschmidt has been in a variety of management positions within the hospital pharmacy field. Pharmacy is undergoing a clinical transformation, and Dr. Kleinschmidt would like pharmacy to be a leader during this transition. As pharmacists, we have an opportunity to change healthcare models to better serve our patients, and this is not a responsibility that should be taken lightly. We possess an outstanding clinical, practical, and prospective ideology that can benefit all aspects of healthcare.
Laura R. Kroon, PharmD
Dr. Laura Kroon is a 2015 graduate from the University of Kentucky College of Pharmacy. She completed her PGY1 pharmacy residency at Frankfort Regional Medical Center in Frankfort, KY. During this time she also completed a teaching certificate through the Sullivan University College of Pharmacy. She is now completing a PGY2 pharmacy admin residency at the Community Health Systems corporate office with responsibilities at the Tennova Healthcare – Clarksville hospital.
Nicole C. Lefever, PharmD
Nicole LeFever, a Clinical Pharmacist with roughly 10 years’ experience in the Acute Care Setting, completed her Doctorate in Pharmacy at the University of Florida in 2007. Nicole spent the first 6 years of her pharmacy career as a Staff Clinical Pharmacist at Wuesthoff Medical Center Rockledge (a 298 bed full service acute care hospital) and 4 years ago transitioned into the role of Clinical Coordinator at Wuesthoff. Nicole has also been a Clinical Assistant Professor with the University of Florida, College of Pharmacy since 2013 and additionally conducts guest lectures at various institutions with primary focuses on Antimicrobial Stewardship, Pain Management, Addiction Medicine, and Psychiatric Pharmacotherapy.
Katherine Smith, PharmD
Dr. Katherine Smith received her Doctor of Pharmacy from the University of Arizona College of Pharmacy in 2011 and then completed a postgraduate year 1 (PGY1) pharmacy practice residency at the Southern Arizona VA Healthcare System in 2012. She is currently serving as the Women’s Center pharmacist at Northwest Medical Center (NMC) in Tucson, AZ. Dr. Smith is actively involved in the Community Health Systems (CHS) Neonatal Intensive Care Unit (NICU) Workgroup, whose mission is to develop evidence‐based, standardized content for neonatal care, as well as the NMC Maternal‐Child Safety Committee. She serves as preceptor for the PGY1 Management Conference residency experience, in addition to precepting Introductory Pharmacy Practice Experience (IPPE) and Advanced Pharmacy Practice Experience (APPE) students.
Kathryn E. DeSear, PharmD, BCPS, AAHIVP
Dr. Kathryn (Kate) DeSear earned her doctor of pharmacy degree from the University of Florida. She subsequently completed a PGY1 pharmacy practice residency in St. Petersburg, FL at the Bay Pines VA. She completed a second year residency (PGY‐2) in infectious diseases at the University of Florida Health Shands Hospital. Dr. DeSear has practiced as an antimicrobial stewardship specialist since 2012. She joined the corporate CHS team in 2016. She serves as the stewardship manager for CHS facilities and participates in the fellowship and residency learning experiences. She also serves as a preceptor for APPE students at the University of Florida and holds a clinical assistant professor position within the Department of Pharmacotherapy and Translational Research.
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 1
2016 Pharmacy Education Series
November 16, 2016Pharmacy Pearls 2016
2
Submission of an online post‐test and evaluation is the only way to obtain CE credit for this webinar
Go to www.ProCE.com/CHSRx Webinar attendees will also receive an email with a direct link to the
web page Print your CE statement of completion online
– Credit for live or enduring (not both)
Deadline: December 16, 2016 CPE Monitor (applicable to pharmacists and pharmacy technicians)
– CE credit automatically uploaded to NABP/CPE Monitor upon completion of post‐test and evaluation (user must complete the “claim credit” step)
Online Evaluation, Self-Assessmentand CE Credit
Attendance Code
Code will be provided at the end of today’s activity
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 2
How to Ask a Question
Locate menu bar on your computer desktop
Click orange arrow button
Menu box will open
Type question into question box
Click Send
Do not close menu box
– This will disconnect you from the Webcast
Please submit questions throughout presentation
Click No!
Enter question
Click Send
3
Accessing PDF Handout
Click the hyperlink that is located directly above the question box
Do not close menu box
– This will disconnect you
from the Webcast
Close other applications
No!
Clickhyperlink
4
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 3
2016 Pharmacy Education Series
5
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. None of the presenters have any relevant commercial and/or financial relationships to disclose.
Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
November 16, 2016Pharmacy Pearls 2016
CE Activity Information & Accreditation
ProCE, Inc. (Pharmacist CE)
– 2.0 contact hours
6
Funding:This activity is self‐funded through CHSPSC.
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 4
Pharmacy Pearls 2016Introductory Remarks
Trent A. Beach, PharmD, MBA, MHA, BCPS, FASHP, FACHE
Director; Clinical Services and Education
CHS Professional Services Corporation, Franklin, Tennessee
7
ANTIMICROBIAL STEWARDSHIP andRENAL DOSING ENHANCEMENTMargaret Babin, Rph, BS PharmPharmacy Clinical CoordinatorTomball Regional Medical CenterTomball, Texas
8
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 5
OBJECTIVES Participant will be able to optimize antibiotic dosing utilizing
patient’s renal function in conjunction with culture and sensitivity reports.
9
Disclosures
I have no relevant conflict of interests to disclose
10
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 6
TRMC Renal dosing protocol policy
4CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Sixth Informational Supplement. CLSI document M100-S26. Wayne, PA: Clinical and Laboratory Standards Institute ; Online-Accessed May 2016.8Tam, V et al. Pharmacokinetics and Pharmacodynamics of Cefepime in Patients with Various Degrees of Renal Function. AntimicrobialAgents and Chemotherapy. 2003;47(6):1853-1861.17DeRyke CA, Lee SY, Kuti JL, Nicolau, D. Optimizing Dosing Strategies of Antibacterials Utilising Pharmacodynamic Principles. Drugs.2006;66(1):1-14
11
Clinical Data Bhat et al
Evaluated 204 episodes of Gram-negative bacteremia treated with 1-2 gm IVPB every 12 hours of cefepime
55% of patients with MIC > 8 mcg/mL died
25% of patients with MIC < 8 mcg/mL died
Bhat SV, et al. Antimicro AG Chemo 2007;51:4390.
12
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 7
CSLI Recommendations for Cefepime Before 2014 Enterobacteriaceae with MICs < 8 mcg/mL were
considered susceptible (regardless of dose or interval). Since 2014, MICs of 4-8 mcg/mL are considered susceptible
depending on dose of cefepime ordered Susceptible-Dose-Dependent (SDD): “susceptibility of an
isolate is dependent on the dosing regimen that is used in the patient”
Performance Standards for antimicrobial susceptibility testing. Twenty-fourth supplement. CLSI Document M100-S24. Wayne, PA 2014
13
Susceptibility test Interpretive Criteria Cefepime
*Isolates of Enterobacteriaceae with intermediate susceptibility, use a dose of 2 gm every 8 hours in patients with normal renal function
Cefepime for Injection [package insert]. Paramus, NG: WG CriticalCare: 2014
14
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 8
Resources Review CHS Antimicrobial Stewardship March 2016 webinar
Interpreting MIC in Antimicrobial Susceptibility Testing by Thao Nguyen, PharmD, BCPS
CSLI-M-100 document published yearly
New in 2016: read only access available at http://clsi.org/m100/
15
BLEEDING RISK STRATIFICATION FOR ANTICOAGULATION SELECTION
IN PCI
Presented By: Robley Bartholomew, PharmD, PGY2 Pharmacy Administration Resident‐‐Clinical Support & Service
Lines 16
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 9
Presentation Objectives
1. Understand current clinical initiative
2. Be able to discuss background information regarding calculator and clinical initiative
3. Utilize the bleeding risk tool to assist in anticoagulation selection
17
Angiomax® to Unfractionated Heparin
•ISAR‐REACT/ISAR‐REACT 3A – Reduced loading doses (100 units/kg) result in non‐inferiority to bivalirudin with regard to the composite of death, myocardial infarction, urgent target‐vessel revascularization due to myocardial ischemia with in 30 days, or major bleeding
•HEAT‐PPCI – Reduced incidence of major adverse ischemic events including composite of all‐cause mortality, cerebrovascular accident, reinfarction, or unplanned target lesion revascularization with no increase in bleeding complications when comparing heparin 70 units/kg against bivalirudin
•MATRIX – Similar impact on composite of urgent target‐vessel revascularization, definite stent thrombosis, or net adverse events when compared against bivalirudin with heparin doses of 70 to 100 units/kg
•ISAR‐REACT/ISAR‐REACT 3A – Reduced loading doses (100 units/kg) result in non‐inferiority to bivalirudin with regard to the composite of death, myocardial infarction, urgent target‐vessel revascularization due to myocardial ischemia with in 30 days, or major bleeding
•HEAT‐PPCI – Reduced incidence of major adverse ischemic events including composite of all‐cause mortality, cerebrovascular accident, reinfarction, or unplanned target lesion revascularization with no increase in bleeding complications when comparing heparin 70 units/kg against bivalirudin
•MATRIX – Similar impact on composite of urgent target‐vessel revascularization, definite stent thrombosis, or net adverse events when compared against bivalirudin with heparin doses of 70 to 100 units/kg
Heparin versus Bivalirudin:
7/17/2015 18
*Angiomax® (bivalirudin) use during PCI is associated with significant increase in medication cost when compared with unfractionated heparin
(~$500/vial versus <$10/vial)
C
* Details Available on the CHS Pharmacy Intranet Page
Heparin Dosing:With GPIIb/IIIa
inhibitor: 50‐70 units/kg
Without GPIIb/IIIaInhibitor:
70‐100 units/kg
Other Health Systems Using Heparin over bivalirudin:‐Ross Heart Hospital, The Ohio State University Medical Center‐The Cleveland Clinic‐Beth Israel Deaconess Medical Center
18
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 10
Background
• 2013 AHA/ACC Guideline for the Management of ST‐Elevation Myocardial Infarction– “Bivalirudin preferred over UFH with GP IIb/IIIa receptor antagonist in patients at high risk of bleeding”
– Class IIa recommendation (Level of Evidence B)
• 2014 AHA/ACC Guideline for the Management of Patients With Non–ST‐Elevation Acute Coronary Syndromes – “In patients with NSTE‐ACS undergoing PCI who are at high risk of bleeding, it is reasonable to use bivalirudinmonotherapy in preference to the combination of UFH and a GP IIb/IIIa receptor antagonist”
– Class IIa recommendation (Level of Evidence B)19
Risk Stratification Tool
• NCDR Report– Rao et al. 2013 – CathPCI Registry– Over 1 million PCI procedures from 1142 sites– Most predictive factors were:
1. female sex 2. shock 3. salvage PCI
• Developed a Pre‐Procedure Bleeding Risk Model• Utilizes a 10 variable scoring system
• Stratification and anticoagulant selection
• Rao SV, McCoy, LA, Spertus JA, at al. An updated bleeding model to predict the risk of post‐procedure bleeding among patients undergoing percutaneous coronary intervention. JACC: Cardiovascular Interventions, VOL 6, No. 9, September 2013:897‐904 20
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 11
PCI Pilot
• Results from bleeding risk pilot at Deaconess Hospital in Spokane, WA
Risk Stratification for Anticoagulant Use for PCI Bleeding
July 2016 August 2016September 14,
2016Post‐Implementation
Heparin Bival % Bival Heparin Bival Heparin Bival Heparin Bival% Use of Suggested
Low Risk0 5 100% 5 1 1 0 6 1 85.7%
Medium Risk0 18 100% 23 1 7 0 30 1 96.7%
High Risk0 7 100% 2 7 0 2 2 9 81.8%
Total Patients0 30 100% 30 9 8 2 38 11 91.8%
21
NCDR Bleeding Risk Stratification Tool
22
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 12
Conclusion
• Heparin for low to moderate bleeding risk patients
• Guideline recommendations for bivalirudin in PCI for high bleeding risk patients
• NCDR Report
– Bleeding Avoidance Strategies
– Simplified Model
• Calculator provides objective method for stratification
23
References
• Schulz S, Mehilli J, Neumann FJ, et al. ISAR‐REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. European Heart Journal, 2010; 1‐10.
• Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT‐PPCI): an open‐label, single centre, randomised controlled trial. Lancet 2014; 384: 1849–58
• Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. NEJM 2015: 1‐13.
• Rao SV, McCoy LA, Spertus JA, et. al. An updated bleeding model to predict the risk of post‐procedure bleeding among patients undergoing percutaneous coronary intervention. Journal of the American College of Cardiology 2013;6: 897‐904.
24
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 13
IDSAPPA²SC’s Infectious Disease Specialist Access Pilot Project
Presented by James Bunch PharmD BCPS
25
Objectives Explain some of the unique challenges to
implementing a true ASP in a community hospital.
Define A²SC Define IDSAPP
26
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 14
Developing an ASP Can be Challenging
One of the biggest challenges we had here was lack of ID trained professionals.
We have no ID trained Physicians. We have no ID trained Pharmacists. Once our ASP began our lead and our
other pharmacists continually found themselves past the scope of their knowledge base and comfort level.
27
Tackling our Challenge We enrolled most of our pharmacists in
SIDPA classes or MAD-ID basic. We sent our ASP leader to MAD-ID
advanced.◦ BUT we still found ourselves deficient of one key ingredient.◦ Luckily for us many hospitals in our state had the same problem…no easy access to ID consult.
28
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 15
29
The Alaska Antimicrobial Stewardship Collaborative
Is a collaboration of acute care and long-term care hospitals across the state.
Strives to develop strategies to ensure appropriate antibiotic use.
30
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 16
A2SC’s Goal To see that “all patients in Alaska will
receive the right antibiotic at the right time and only when necessary.”
31
Some of the Benefits of A²SC Shared clinical pathways for treatment of
infections. Pooled data for regional antibiograms. Networking IDSAPP
32
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 17
Infectious Disease Specialist Access Pilot Project (IDSAPP)
IDSAPP is a 6 month/1year pilot Designed to help bridge the gap between
local talent accessing trained infectious disease specialists and their expertise.
33
Requirements for Participation Membership in ASHNHA Provide a CEO Letter of Commitment to
support antimicrobial stewardship activities.
Assemble Antimicrobial Stewardship Program team including a pharmacist and/or physician.
Collect basic Infectious Disease Specialist utilization data.
34
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 18
Goal of IDSAPP Enhance infectious disease case review. Help to optimize antibiotic treatment. Strengthen local ID resources through:◦ Education ◦ Training
35
Education Benefits of IDSAPP: Six educational monthly webinars led by
an ID physician. ◦ Antibiotic stewardship prospective audit and feedback: basic structure and approach◦ Respiratory tract infections◦ Skin and soft tissue infections◦ Urinary tract infections◦ Fever, neutropenia, and sepsis without a source◦ Osteomyelitis, septic arthritis, and endocarditis
36
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 19
Training Benefits of IDSAPP: In addition to the monthly webinars there
are weekly/bi-weekly case review calls with ID Specialist.
These calls are designed to provide expert opinion as well as train others on how to approach treatment of infections from a local antimicrobial stewardship standpoint.
37
References: www.ashnha.com
38
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 20
Access DatabaseIt’s utility in managing pharmacy controlled substance auditing.
Jo Ann Gibbs, Pharm D, BCPS
Byrd Regional Hospital
39
Objectives
The purpose of this discussion is to demonstrate the capabilities of a simple Access Database and show how it can be used to capture documents, run reports, and provide accountability in your controlled substance auditing process.
40
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 21
Learning Objectives
• The learner will be able to:
– Recognize the basic capability of Access.
– Recognize the advantage of the document storage function.
– Recognize utility of the query function.
– See the possible utility in a controlled substance auditing program.
41
Access• Access is a Microsoft Program that is part of the Office group of tools like Word and Excel. You should be able to activate it on your computer.
• It has expanded functions, but works like Excel from a table that can be sorted.
• It assigns each row with a unique ID number that can be deleted, but cannot be re‐used.
• You can design queries that download requested data into an Excel file that can be further manipulated.
• You can attach documents to the file, allowing you to eliminate hunting for paperwork.
• It is independently managed.
42
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 22
Overview of Our Database
43
Table
44
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 23
Data Entry Form
45
Add a Record
46
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 24
Adding Documents
47
Save File
48
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 25
Record Search
49
Query
Right Click
50
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 26
Query‐cont.
51
Data Analysis in Excel
• You can sort by date range, nurse involved, and drug.
• Helpful in proactive diversion reporting to nursing.
• Send a report of open discrepancies to the CNO. If she doesn’t become involved in helping clear up the issues copy the CEO.
52
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 27
Sample# LastName Acct DrugName Strength Qty Date Nurse SummaryOfEvent Unit
234 . . Hydrocodone/Apap 7.5/325mg 1 08‐Aug‐16 Ashley HNeed to find out which patient the medication was administered to..
ER
236 Smith 103123 Hydrodocone/Apap 10/325mg 1 13‐Aug‐16 Elizabeth Found no charting for the medication indicated, see attached form
MS2
235 Will 363123 Hydromorphone 2mg/ml 1 10‐Aug‐16 Julie Found no order or charting for the medication indicated…see attached form
ER
238 Mouse 363123 Hydromorphone 1mg/ml 1 16‐Aug‐16 Loree
Found no charting for the medication pulled @10:02…the 10:00 pull was charted…found no return or waste..see attached form
MS2
240 Duck 363123 Ketorolac 30mg/ml 2 16‐Aug‐16 David MFound no return or waste for the medication indicated, chart states that the patient refused the med
ER
243 Watson 3641232 Hydrocodone/Apap 10/325mg 1 24‐Aug‐16 Loree AFound no charting for the medication indicated..see attached form
MS2
53
Reporting by Date and Nurse
0 1 2 3 4 5
Amanda
Katherine
Crystal
Kristen
Lance
Ashley
Megan
Julie
Elizabeth
Jennifer
Lorie
David
Number of Issues by NurseJuly & August 2016
54
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 28
My Experience
• We have a group folder on the shared drive that can only be accessed by pharmacy. We keep this data in that folder.
• Anyone who is doing your controlled substance auditing can fill out the form.
• The data is stored from the form to the table, which can be queried.
55
My Experience
• When a question arises during the audit:– Info is entered in the form.
– The Pyxis report is scanned and attached to the form in the database.
– A copy of the form is printed.
– The Pyxis report is stapled to the printed form and given to the nurse manager.
– They write on the form and send it back to me. We scan and attach the information in our database.
56
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 29
My Experience
• If they don’t respond, I do a query each week and send open requests in a table to the CNO.
• If they say, I can’t find the info it is easy to recreate from the database.
• If it can be closed, we simply close it in our database.
• If it needs to go to a Theft/Loss report, we update our form and scan and attach any pertinent data.
57
My Experience
• This has organized my data so it can be used in a meaningful way.
• It has given the CNO specific information to react to when I need her assistance with motivation.
• It is not perfect, but it has made my job of oversight much easier.
58
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 30
Conclusion• If you would like to learn more about Access there are free tutorials on You Tube.
• I have a template that can be shared if you are interested in it. You can simply use a copy of mine and start entering your own information on the Data Entry Form.
• There is a learning curve. It took us about 2 months, but I started with You Tube tutorials.
• It is not perfect, but it worked for me.
59
Sentri7® Tips and Best Practices
Sue V. Ie, PharmD
Fellow, Health Information and Clinical Outcomes
Community Health Systems and Wolters Kluwer Health
Franklin, TN
November 16, 2016
60
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 31
Disclosure
Postdoctoral Fellow for Community Health Systems and Wolters Kluwer Health
61
Objective
Share Sentri7 tips and solicit best practices to share within the health system
62
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 32
Standardize rule names to allow for streamlined sort and display when viewing patient rule matches
Order your rules and tabs using the Position Icons in the Rules Tab Note: Not available if the rule was created and shared by another administrator
Basic Optimization of Sentri7®
63
Sort and view Rule Matches by the priority of the rules in Sentri7® when working in the Patients Tab
Assign priority levels to the rule set Note: Default priority level is Medium
Basic Optimization of Sentri7®
64
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 33
Work efficiently in the Patient Card to view all Rule Matches for a patient and document interventions directly
Basic Optimization of Sentri7®
65
Reduce the variances and numbers of criteria for current and future alerts
Minimize “Advanced Logic” in your alerts
Click “Select Lab Names”
Select value based on the string in the search box
See multiple values added to the alert
Results added to the alert will not appear if already included
Chemistry/Lab Criteria Enhancements
66
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 34
Use the envelope icon to turn on and off email notifications Note: Notifications are user‐specific and rule‐specific
Tip: Use the Notifications Center to turn on and off all notifications with one click and perform a retrospective patient review
Email Notifications
67
Relevant Drugs – appears for any rules that include drug name criteria Helps to identify the drug(s) that qualified a patient on an alert Displays active and discontinued medications from the past 7 days that were mentioned in the drug name criteria
Tip: Clean up columns in the relevant drugs display by using the widget
Relevant Drugs Link
68
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 35
Shows culture information
View Options: last 24 hours, last 3 days, last 7 days [default], last 30 days, or all
View preliminary results or click Show Final Only
Tip: Do a side‐by‐side comparison by clicking View Multiple
Microbiology Link
69
Tip: Embed hyperlinks to outside references or on your intranet
Use this HMTL example for your own links:
<br><a href="www.Sentri7.com" target="_blank"> XXXXX</a>
*Replace www.Sentri7.com the URL you would like to reference
*Replace XXXXX with the text you would like to appear for the link
Suggested Action
70
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 36
Review = Temporary Record, “Virtual Sticky Note” Patient is “greyed‐out” on dashboard for length of reset interval
Temporary, removed when the patient disqualifies for the rule
Enable “Advanced Review Options” This allows next steps to be set
Enable Advanced Review Options
71
http://tinyurl.com/sentri7form
Purpose Provide all CHS Sentri7 users with a centralized method of communication with the CHS Sentri7 Advisory Committee
Solicit and compile Sentri7 tips and best practices to share within the health system
Identify areas of interest for Sentri7 educational materials and webinars
Online CHS Sentri7 Form
72
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 37
73
http://tinyurl.com/sentri7form
Actions Available Sign‐up for Sentri7 mailing lists with tips, best practices and announcements
Submit requests, share best practices, provide feedback for all matters related to Sentri7
Online CHS Sentri7 Form
74
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 38
Sentri7® Help and Training Link Announcements
Training Videos and Manuals
Direct Support (800) 341‐0450 7:00AM‐7:00PM CT
support@pharmacyonesource.com
CHS Sentri7® Advisory Committee http://tinyurl.com/sentri7form
Help & Training
75
Questions or Feedback?
Submit them online at:
http://tinyurl.com/sentri7form
76
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 39
Medication ReconciliationA Pharmacy‐Led Proposal
George Jossell PharmDCandidate 2016 77
What are we doing now?
78
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 40
Rationale for change
The rationale for introducing pharmacy-led medication reconciliation is to improve our quality of care. This is truly patient centered care where metrics become more that just a number with impersonal measures.
Patient centered care means we place the patient’s needs above all else.
79
Evidence to Support Change
Pharmacists are uniquely skilled to provide optimum medication information to the staff which can be offset by the many task-hours spent intervening to obtain patient demographics of height, weight, and allergy profiles from front-line caregivers. Performing this functionality upon admission would not only improve patient outcomes, but also satisfy frustrations throughout the hospital staff by the provision of these parameters including patient medication histories.
80
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 41
Evidence
81
Statistical Analysis to Support Change
Totals Pharmacy
1/25 – 2/26/16
ED staff
(previous 30dys)
# Histories taken 66/80 (82.5%) 189/244 (77.45%)
# M‐F 66/66 (100%) N/A
Average time (1) 0.25 hours 0.25 hours
Daily hours 2.0 2.0
24 hour metric 66/66 (100%) 65%
Core measure
50% threshold
Exceeded Met
82
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 42
Pharmacy Process
Advanced pharmacy practice experience students (APPE), under my supervision will guide this project with the assistance of staff certified pharmacy technicians. The project began in January 2016, continuing as a pilot project through February 2016.
83
Associated Cost Metrics
Pharmacy can absorb the hours associated with medication reconciliation as determined in the pilot.
We anticipate an investment of 2 hours per 8 hour work day which can be built into our current tasking since pharmacy has some task associated downtime from minimizing the sterile compounding tasks and ordering premixed medications.
84
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 43
Improvements Anticipated
MU Measures 0% 20 40 60 80 100
CPOE for medication orders
CPOE for laboratory
CPOE for radiology ePrescribe (eRX) and transm
SoC ‐ eTransmit (all disch)
Patient education resources
Medication reconciliation
Patient data available online
Last 6 M th
% Met Denominator Met Not met
86.73 4356 3778 578
58.44 3682 2152 1530
68.99 329 227 102
0 1143 0 1143
30.14 272 82 190
45.33 236 107 129
77.45 244 189 55
100 261 261 0
5.36 261 14 247
Record Demographics
Record vital signs
Record smoking status
Maintain allergy list
Maintain active medication lis
Last 6 M th
% Met Denominator Met Not met
97.88 236 231 5
87.28 236 206 30
89.47 209 187 22
95.76 236 226 10
99.15 236 234 2
97.88 236 231 5
85
Marketing Perspective: Safety Profile
Based on the meaningful use measures published on the previous slide, a pharmacy-led medication reconciliation team would improve the quality of care on this metric between 5 – 22.5 %
These improvements would provide a potential marketing honor when compared to similar hospitals on the basis of safety.
86
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 44
Conclusion
87
Conclusion
These results and the accompanying evidence from studies cited show that medication and pharmacy are important partners in the health care forum.
Pharmacy personnel can and will improve the quality of care from a medication reconciliation perspective.
The evidence is clinically significant.
88
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 45
The End
89
Heparin and ImpellaThe Systemic Question
Michael Kleinschmidt, PharmD, BCPSDirector of PharmacyBrandywine Hospital
90
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 46
• Background
• Indications
• Scenarios
Heparin and Impella
Overview and Discussion Points
91
Impella Device
• Percutaneous left ventricular assist device
• Used in percutaneous interventions to take workload off heart
• Also used in instances of cardiogenic shock
• Myocardial infarction
• Myocarditis
• Endocarditis
• Drug Overdose
Heparin and ImpellaBackground
92
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 47
Impella Device
• LV end diastolic pressure, wall tension, work and myocardial oxygen demand
• Mean arterial pressure, diastolic pressure, cardiac output
• Pulmonary capillary pressure and right ventricular afterload
Heparin and Impella
93
Impella Device
Heparin and Impella
Operational Screen
Actual Device
94
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 48
Impella Device
• Heparin purge solution is needed to keep Impella device patent and non‐occluded
• Concentrations range from 6.25 units/mL to 50 units/mL
• Brandywine Hospital normal concentration = 50 units/mL
• Purge rate can only fluctuate from 4 – 20 mL/hour
• Will give covering RN units of heparin/hour on main screen
Heparin and ImpellaBackground
95
1. High Risk PCI
• Impella Device does not travel with patient to floor
• Only systemic heparin (25000 units/250 mL to be used)
• No need for heparin Purge Solution
2. Cardiogenic Shock
• Impella Device does travel with patient to floor – ICU only
• 2 Unique Heparin Solutions
• Purge • 25000 units/500 mL
• Systemic • 25000 units/250 mL
Heparin and ImpellaIndications
96
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 49
Heparin and Impella
For all Scenarios consider
Therapeutic aPTT range 50‐70 seconds
97
Heparin and ImpellaScenario 1
• Patient arrives to ICU from Impella procedure
• Physician orders systemic heparin
Solutions
• STAT aPTT
98
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 50
Heparin and ImpellaScenario 2
• Impella running in ICU
• Purge Solution actively running
• Baseline aPTT in unit = 80 seconds
Solutions
• DO NOT START SYSTEMIC INFUSION
• Change concentration of Purge solution• Consider 25 units / mL (12500 units / 500 mL)
• Redraw aPTT in 4 hours
99
Heparin and ImpellaScenario 3
• Impella running in ICU
• Purge Solution actively running
• Baseline aPTT in unit = 15 seconds
Solutions• START SYSTEMIC INFUSION• Determine which systemic heparin to use
• VTE or Cardiac/Non‐VTE• Calculate the total units/hour to be delivered = Number B
• Obtain units/hour being delivered from Impella device = Number A
Number B – Number A = Total units/hour needed from systemic heparin infusion100
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 51
Heparin and ImpellaScenario 4
• Impella running in ICU• Purge Solution and systemic heparin actively
running• Impella Purge solution flow rate adjusted
Solutions• STAT aPTT• Obtain units/hour being delivered from Impella device = Number A• Look at which systemic heparin is in use:
• VTE or Cardiac/Non‐VTE• Calculate the total units/hour to be delivered = Number B
Number B – Number A = Total units/hour needed from systemic heparin infusion101
Heparin and ImpellaScenario 5
• Impella stopped in ICU
• Purge Solution and systemic heparin actively running
Solutions
• Stop Purge solution
• Obtain aPTT
• Adjust systemic heparin according to protocol
102
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 52
Taking Flight on Fighting Inappropriate EPINEPHrine Use
Laura Kroon, PharmD
PGY2 Pharmacy Administration Resident
Laura_Kroon@chs.net
103
Objective
• Discuss epinephrine best practices for preparation and administration within the hospital.
104
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 53
EPINEPHrine
• Mechanism of Action:
– sympathomimetic catecholamine acting on alpha‐and beta‐adrenergic receptors
• Indications: ‐ Anaphylaxis‐ Adjunct for local anesthesia‐ Asthma‐ Blood coagulation disorder‐ Congestion of mucosa‐ Cardiopulmonary
resuscitation
‐ Excessive uterine contractions
‐ Glaucoma‐ Hypersensitivity reaction‐ Syncope
Epinephrine. In: DRUGDEX® System105
Concerns of EPINEPHrine
Drug shortages
Concentration(i.e. 1:10,000 vs. 1:1,000)
Confusion with ePHEDrine
Route of administration(i.e. IM/subQ vs. IV infusion vs. IV push)
Cost
106
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 54
Error‐prone EPINEPHrine Kit
• Proposed by a physician practicing emergency medicine in Ohio
• Includes: empty Altoids® tin, EPINEPHrine 1 mg ampule or vial, alcohol pad, syringe
• ISMP’s Acute Care Medication Safety Alert®: Not recommended for use
Safety brief: An EPIPEN replacement idea that’s likely to lead to dosing errors. Acute Care ISMP Medication Safety Alert.107
Polling Question
True or False
A patient experiencing an anaphylactic reaction should receive EPINEPHrine 1 mg/mL via IV push.
108
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 55
EPINEPHrine for Emergent SituationsIndication Dose Route
EPINEPHrine 1 mg/mL (vial/ampule)
Anaphylaxis/Hypersensitivity reaction
0.2‐0.5 mg IM or subQ
EPINEPHrine 1 mg/mL (vial/ampule used to prepare infusion)
Severe refractory bradycardia, cardiac arrest, VF, VT
2‐10 mcg/min (titrated to effect)
IV infusion
EPINEPHrine 1 mg/10mL (prefilled syringe)
Cardiac arrest 1 mg IV push
VF = Ventricular fibrillation; VT = Ventricular tachycardia110
EPINEPHrine Anaphylaxis/Hypersensitivity Reaction Kit
Kit contents:
1 mL vial or ampule (include filter needle if ample) of EPINEPHrine 1 mg/mL
1 mL syringe
alcohol wipe
IM/subQ needle for administration
kit label with administration instructions
What price must we pay for safety? Excessive cost of EPINEPHrine auto‐injectors leads to error‐prone use of ampuls or vials and unprepared consumers. Acute Care ISMP Medication Safety Alert.
EPINEPHrine Anaphylaxis Dosing Concentration:1 mg/mL
Adults: 0.2 mg (0.2 mL) – 0.5 mg (0.5 mL) IM or subQ q5 min PRN
Infants/Children/Adolescents: 0.01 mg/kg/dose IM or subQ
** Filter if from ampule** DO NOT GIVE IV
Weight15‐29 kg (33‐66 lbs) ≥ 30 kg (≥ 66 lbs)0.15 mg (0.15 mL)
q5 min PRN0.3 mg (0.3 mL) q5 min PRN
111
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 56
EPINEPHrine Kit for Cardiac Indications
Kit contents:
1 mL vial or ampule (include filter needle if ampule) of EPINEPHrine 1 mg/mL OR10 mL syringe of EPINEPHrine 1 mg/10mL
normal saline 250 mL
3 mL syringe
alcohol wipe
needle
kit label with administration instructions
EPINEPHrine for Cardiac Use ‐ ADULT
Dilute 1 mg EPINEPHrine *1 mg/mL vial/ampule OR1 mg/10mL syringe* in 250mL NS
Adults: 2‐10 mcg/minute (30‐150 mL/hour) IV infusion titrate PRN (max 120mcg/minute)
1 mg EPINEPHrine in NS 250 mL (4 mcg/mL)*Undiluted EPINEPHrine 1 mg/mL cannot be given IV push*
112
References
Epinephrine. In: DRUGDEX® System [database on the Internet]. Greenwood Village, CO: Thomson Micromedex; 2016.
Hauser C. Epinephrine injection kit for under $10. abc22now. http://abc22now.com. Accessed October 26, 2016.
Pennsylvania Patient Safety Authority. An update in the “Epi”demic: events involving EPINEPHrine. Pa Patient Safe Advis. 2009;6(3):102‐3.
Safety brief: An EPIPEN replacement idea that’s likely to lead to dosing errors. Acute Care ISMP Medication Safety Alert. September 08, 2016:1–2.
What price must we pay for safety? Excessive cost of EPINEPHrine auto‐injectors leads to error‐prone use of ampuls or vials and unprepared consumers. Acute Care ISMP Medication Safety Alert. http://www.ismp.org/newsletters/acutecare/showarticle.aspx?id=1145. Published August 11, 2016. Accessed October 26, 2016.
113
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 57
Vasopressin Optimization
Nicole LeFever, PharmD
Clinical Pharmacy Coordinator
Wuesthoff Medical Center Rockledge
Clinical Assistant Professor ‐ University of Florida
114
Objectives
•Vasopressin Brief Overview
•Vasopressin in Septic Shock
•Vasopressin removal from ACLS Guidelines
•Vasopressin Product History
115
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 58
Vasopressin:Basic Pharmacology
•Vasopressin (arginine vasopressin, AVP; antidiuretic hormone, ADH)
•Nonapeptide hormone formed in the hypothalamus and released from the posterior pituitary.
•Primary function is to regulate extracellular fluid volume by affecting renal handling of water
•A potent vasoconstrictor
Product Information: Vasostrict(TM) intravenous injection, vasopressin intravenous injection. Par Pharmaceutical Companies (per FDA), Spring Valley, NY, 2014. 116
Vasopressin:Basic Pharmacology
• Principal sites of action• Blood vessels and kidney• At doses > 0.04 units/hr may decrease GI blood flow
• Works on V1 & V2 receptors
• Vasoconstriction ‐ Vascular V1 receptor stimulation• V1 receptors are coupled to phospholipase C
• The downstream effect causes a calcium release • Causes contraction of vascular and other smooth muscles
• Subsequently causes vasoconstriction• Increases Blood Pressure
• Anti‐diuresis ‐ V2 receptor stimulation• V2 receptors are coupled to adenyl cyclase
Product Information: Vasostrict(TM) intravenous injection, vasopressin intravenous injection. Par Pharmaceutical Companies (per FDA), Spring Valley, NY, 2014. 117
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 59
Vasopressin:Basic Pharmacology
•Side Effects• Common
• Cardiovascular: Bradyarrhythmia, Tachyarrhythmia• Endocrine metabolic: Hyponatremia
• Serious• Cardiovascular: Atrial fibrillation, Cardiac arrest, Decreased cardiac function, Hemorrhagic shock, Myocardial ischemia, Right heart failure
• Dermatologic: Gangrenous disorder, Cutaneous• Gastrointestinal: Mesenteric vascular insufficiency• Renal: Renal impairment, acute• Respiratory: Pulmonary edema
• Renal excretion • Elimination Half life of 10 minutes or less
Product Information: Vasostrict(TM) intravenous injection, vasopressin intravenous injection. Par Pharmaceutical Companies (per FDA), Spring Valley, NY, 2014.118
Vasopressin:in Septic Shock
• Proposed for use in septic shock because it is an endogenous peptide with potent vasoactive effects and its circulating levels are depressed in septic shock.
• Indicated for adult patients who are still hypotensive with vasodilatory shock despite proper fluid resuscitation and catecholamine administration.
•According to the Surviving Sepsis Campaign guidelines:
• “Vasopressin should not be the single initial vasopressor, but should be reserved for salvage therapy”.
Dellinger RP et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012. Crit Care Med 2013 Feb; 41:580. 119
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 60
Septic Shock:Hypotension Management
•Surviving Sepsis Campaign recommendation:
• Initial fluid challenge in patients with sepsis‐induced tissue hypoperfusion with suspicion of hypovolemnic
•Start with ≥ 1000 mL of crystalloids
•Achieve a minimum of 30ml/kg of crystalloids in the first 4 to 6 hours.
Dellinger RP et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012. Crit Care Med 2013 Feb; 41:580. 120
Septic Shock:Hypotension Management
• If refractory to fluid resuscitation. . .• Apply vasopressors (for hypotension that does not respond to initial fluid resuscitation to maintain a mean arterial pressure (MAP) ≥65mmHg)
• Catecholamine (norepinephrine or phenylephrine) is first‐line agent.
• Vasopressin as second‐line agent to reduce need for other pressors.
• After first‐line treatment, Vasopressin 0.03 Units/min may be added to norepinephrine (NE)
• Anticipated effect equivalent to that of NE alone.
Dellinger RP et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012. Crit Care Med 2013 Feb; 41:580. 121
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 61
Vasopressin: Dosage and Administration•Septic shock 0.01‐0.07 units/min
•Do NOT discontinue catecholamine • i.e. norepinephrine
•Central line preferred due to risk of skin necrosis
Dellinger RP et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012. Crit Care Med 2013 Feb; 41:580. 122
Vasopressin:Place in ACLS. . .or not•2015 ACLS update
•Vasopressin removed from the ACLS treatment algorithm for cardiac arrest
•No need to routinely stock Vasopressin in Emergency Medicine Carts •aka “Crash Carts”
Link MS, Berkow LC, et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015 Nov 3;132(18 Suppl 2):S444‐64.
123
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 62
VasopressinProduct History•Available until late 2014 as Pitressin®
• No refrigeration was needed
•NDA approved by FDA for Vasostrict® with new refrigeration storage requirement
•Vasostrict® available for purchase late 2014•Vasopressin Pricing History
Timeline Product Pricing (per vial)
Through end of 2014 Pitressin® ~ $3.00
Nov 2014 Vasostrict® ~ 45.00
Oct 2015 Vasostrict® ~ $85.00
Oct 2016 Vasostrict® ~ $120.00
Note: Vasopressin pricing history based on local acquisition costs; your facility pricing may not reflect these numbers124
References
• Product Information: Vasostrict(TM) intravenous injection, vasopressin intravenous injection. Par Pharmaceutical Companies (per FDA), Spring Valley, NY, 2014.
• Dellinger RP et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012. Crit Care Med 2013 Feb; 41:580.
• Link MS, Berkow LC, et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015 Nov 3;132(18 Suppl 2):S444‐64.
• http://www.fda.gov/downloads/forhealthprofessionals/articlesofinterest/ucm446992.pdf
125
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 63
Review of Tdap and Influenza Vaccination in Obstetric Patientsat Northwest Medical Center
Katherine Smith, PharmDWomen’s Center at Northwest Medical Center in Tucson, AZCHS Clinical Pearls PresentationNovember 16, 2016
126
Objective
• Describe the current CDC guidelines for Tdap and influenza vaccination in obstetric patients, and discuss the maternal and fetal benefits of prenatal vaccination.
127
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 64
Tdap Vaccination During Pregnancy
• CDC1
• Provide Tdap during 3rd
trimester of each pregnancy• Protective antibodies are
highest 2 weeks after vaccination• Transplacental transfer of
antibodies provides protection until infant starts DTaP series at 2 months of age
• If not given during pregnancy, provide immediately postpartum
• ACOG2
• Tdap can be safely administered during any stage of pregnancy, but 3rd
trimester is optimal• May vaccinate earlier in
pregnancy due to:• Ongoing epidemics• Wound management• Unknown or incomplete
tetanus vaccination history• All immediate family and
direct caregivers should be vaccinated at least 2 weeks prior to delivery or contact with infant
128
Why is this important?1
• In 2012, there were 48,277 reported cases of whooping cough, the most in over 60 years• Includes 2,269 cases in infants less than 3 months
• 15 infants died
• Half of infants less than 1 year old with pertussis are hospitalized• 67% will have apnea• 23% develop pneumonia• 1-2% will die
• Other serious and life-threatening complications in infants include cyanosis, seizures, and encephalopathy
• Maternal vaccination during pregnancy can protect up to 90% of infants against pertussis
129
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 65
Influenza Vaccination During Pregnancy
• CDC3
• Inactivated influenza vaccine recommended during every flu season (October - March)
• Any time before or during pregnancy
• Nasal spray SHOULD NOT be given (live vaccine)
• ACOG4
• “It is critically important that all obstetrician–gynecologists and all providers of obstetric care advocate for influenza vaccination, provide the influenza vaccine to their pregnant patients, and receive the influenza vaccine themselves every season. This will send a powerful message to all pregnant women that vaccination is very important for the protection of themselves and their unborn children.”
130
Why is this important?5
• Pregnant women are more prone to severe illness, complications, hospitalizations, and death
• Antibodies from maternal vaccination can provide protection up to 6 months after birth and can reduce a child’s risk of contracting influenza ~50%
• CDC Internet panel survey during the 2014-2015 influenza season6
• Among 1,702 pregnant women, 50.3% reported receiving influenza vaccination before pregnancy or during pregnancy
Influenza vaccination rate in pregnant womenwith at least one visit to a health care provider
Provider recommended AND offered 67.9%
Provider recommended but did not offer 33.5%
No recommendation 8.5%131
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 66
Medication Use EvaluationWomen’s Center at Northwest Medical Center
Tucson, AZ
132
Women’s Center at NMC
• Freestanding facility located in Tucson, Arizona• 13 labor and delivery rooms
• 17 mother-baby rooms
• 17-bed Level IIE Special Care Nursery
• Average census: 8 labor patients and 15 mother-baby couplets
• Average 8 deliveries per day, 235 births per month• Primary c-section rate: 12.7% (overall: 26%)
• Average 9.3 patients per month with no prenatal care
133
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 67
Purpose
• To evaluate the timing and appropriateness of Tdap and influenza vaccination in our obstetric population, as according to CDC guidelines
134
Methods
• Report of all births at NMC from 1/1/16 to 3/31/16• FIN number• Patient Age• Delivery Date• Gestational Age• Delivering Physician
• Sorted patients chronologically by delivery date, and chose a convenience sample of 100 patients starting on 1/1/16
• Date range: 1/1/16 – 1/13/16
135
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 68
Methods Continued• Data collected from Cerner EMR:
• Delivery Type • Outpatient Obstetrician• Insurance Coverage• Immunization history:
• Tdap
• When?
• Where was it received?
• If Tdap was not given, why?
• Where was the information
obtained?
• Inactivated Influenza Vaccine (IIV)
• Did the patient receive IIV
during their pregnancy?
• Where was it received?
• If vaccine was not given,
why?
• Where was the information
obtained?
• Patient was called if information was missing from Cerner profile using a standardized script.
136
Summary of DemographicsPatient Age (years)
(n=100)
Average 27.4 ± 5.0
Youngest 18
Oldest 40
Delivery Type(n=100)
Spontaneous Vaginal 65
Induced Vaginal 7
Scheduled C-Section 18
Emergent C-Section 10
Gestational Age at Delivery (weeks) (n=100)
Average 39.0 ± 1.4
Youngest 32.5
Oldest 42.2
Insurance(n=100)
Medicaid 50
Private 41
Self-Pay 7
Tricare 2
137
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 69
Tdap DataWhen did patients receive Tdap vaccination? (n=100)
During pregnancy
1st Trimester (weeks 1-12) 1
2nd Trimester (weeks 13-26) 3
3rd Trimester (weeks 27-36) 49
Received vaccine, but unsure when 1
After delivery 6
Patient did not receive vaccine 13
No information 27
For those that received Tdap, where? (n=60)
Outpatient OB 52 (86.7%)
Northwest Medical Center 6 (10.0%)
Other 2 (3.3%)138
Tdap DataFor those that DID NOT receive Tdap, why not? (n=13)
Patient choice 7 (53.8%)
Qualified, but did not receive at NMC 2 (15.4%)
Severe allergy 1 (7.7%)
Unknown 3 (23.1%)
Not including the severe allergy and NMC miss, who were the OBs for those that DID NOT receive Tdap? (n=10)
Physician A 2 (16.7%)
Physician B 3 (25.0%)
Physician C 2 (16.7%)
Physician D 1 (8.3%)
Physician E 1 (8.3%)
Physician F 1 (8.3%)
For those we had information on, where was the information obtained? (n=73)
Health record 60 (82.2%)
Phone interview 13 (17.8%)
139
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 70
Influenza DataDid the patient receive the influenza vaccine? (n=100)
Yes 62
No 36
Unknown 2
For those that received influenza vaccine, where? (n=62)
Outpatient OB 42 (67.7%)
Northwest Medical Center 7 (11.3%)
Other 4 (6.5%)
Unable to determine 9 (14.5%)
For those that DID NOT receive influenza vaccine, why not? (n=36)
Patient choice 33 (91.7%)
Severe allergy 1 (2.8%)
Qualified, but did not receive at NMC 1 (2.8%)
Unknown 1 (2.8%)
140
Influenza DataNot including the severe allergy and NMC miss, who were
the OBs for those that DID NOT receive the vaccine? (n=34)
Physician A 2 (5.9%)
Physician B 4 (11.8%)
Physician C 9 (26.5%)
Physician D 4 (11.8%)
Physician E 2 (5.9%)
Physician F 3 (8.8%)
Physician G 1 (2.9%)
Physician H 2 (5.9%)
Physician I 4 (11.8%)
Physician J 3 (8.8%)
For those we had information on,where was the information obtained? (n=95)
Health record 90
Phone interview 5141
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 71
Conclusion• Of 73 patients with definitive information available, 49 (67.1%) confirmed as
receiving Tdap vaccine during the 3rd trimester• 13 patients (17.8%) confirmed as not receiving Tdap vaccine at any point
• Of 98 patients with definitive information available, 62 (63.3%) confirmed as
receiving influenza vaccine during pregnancy• 36 patients (36.7%) confirmed as not receiving influenza vaccine
• 2 patients should have received the Tdap vaccine and 1 patient should have
received the influenza vaccine at NMC after delivery, but was never given
• For both Tdap and influenza, patient choice was the most common reason
for not receiving the vaccine
142
Limitations• Incomplete prenatal records
• Some outpatient OB documents lacked the dates of immunization, had conflicting information, or no mention of vaccines at all.
• Improper categorization during admission process• For example: A patient who had already received a flu shot could be
marked as “declined/patient choice” instead of “already received during current flu season.”
• Difficult to reach patients by phone• 29 patients with missing information
• Language barrier
• Small sample size: 100 patients over 13 days143
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 72
How can we improve?
• More consistent prenatal records between providers• Specific section for immunizations • An option for declination, as well as a reason why
• Physician and/or nurse in charge of discharge required to go through final screen and offer missing vaccinations
• Stress the importance of receiving recommended vaccinations during pregnancy• Patient and provider education regarding the benefit of
immunization • Automatic alerts for physicians
144
Project Outcomes
• MUE presentation• Antimicrobial Stewardship Program (ASP) team
• Perinatal Committee
• Pharmacy & Therapeutics Committee
• Nursing education• Staff meetings and daily interaction
145
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 73
Acknowledgements
• Ferena Salek, PharmD, Pharmacy Director, Northwest Medical Center
• Linda Calkins, RPH, MPH, Pharmacy Clinical Coordinator, Northwest Medical Center
• Joseph Howdeshell, PharmD Candidate 2019
• Joseph Murata, PharmD Candidate 2019
146
References1. Pregnancy and whooping cough. Centers for Disease Control and
Prevention. http://www.cdc.gov/pertussis/pregnant/index.html. Updated 27 Jan 2015. Accessed 13 Oct 2016.
2. Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Committee Opinion No. 566. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:1411-4.
3. Pregnant women & influenza (flu). Centers for Disease Control and Prevention. http://www.cdc.gov/flu/protect/vaccine/pregnant.htm. Updated 28 Sept 2016. Accessed 13 Oct 2016.
4. Influenza vaccination during pregnancy. Committee Opinion No. 608. American College of Obstetricians and Gynecologists. Obstet Gynecol2014;124:648-51.
5. Flu vaccine safety and pregnancy. Centers for Disease Control and Prevention. http://www.cdc.gov/flu/protect/vaccine/qa_vacpregnant.htm. Updated 25 Aug 2016. Accessed 13 Oct 2016.
6. Ding H, Black CL, Ball S et al. Influenza vaccination coverage among pregnant women: United States, 2014-15 influenza season. Morbidity and Mortality Weekly Report. 18 Sept 2015. 64(36):1000-5.
147
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 74
Antimicrobial Stewardship Updates
Kate DeSear, PharmD, BCPS, AAHIVP
Antimicrobial Stewardship Manager
148
Formulary Updates
• Gram Positive strategy • On pharmacy intranet under Antimicrobial Stewardship Initiatives: Legacy and CHS14
• Includes change in formulary status (category B) & restrictive criteria for daptomycin, ceftaroline, linezolid
• You should have reviewed this with your local AS Committee and passed through local P&T, embed into EHR if possible
• Other formulary and clinical initiatives• Topical acyclovir, penciclovir, docosanol category C with block
• Lipoglycopeptides (dalbavancin & oritavancin) category C with block 149
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 75
Gap analyses sent – please review and prioritize next steps for your AS program
Toolkit now available
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 76
Survey and Transcript Key
152
Download Helpful Tools
153
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 77
Upload your facility examples
Attach your examples and/or enter description of relevant process…
154
Gram Positive Strategy• Gram Positive Toolkit
• Clinical decision algorithm• Description: Flow chart walking through clinical decision process to navigate criteria for use with flow on front and short explanation on back
• Intent: For use by pharmacists with order verification job duty to aid in impromptu discussions with prescribers
• Features: • Short explanations of clinical decisions• May be printed on 1 page, front and back
• Expanded evidence summary• Description: Further breakdown and explanation of literature behind clinical decisions on algorithm
• Intent: For use after discussion with prescribers for pharmacist self‐edification to feel more comfortable in future discussions
• Features: • All sections hyperlinked to algorithm, click on any decision point for further explanation
• Daptomycin Physician Support Tool• Description: A detailed literature review of common unapproved indications used by
prescribers• Intent: For use by antimicrobial stewardship lead to discuss with outlier prescribers
155
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 78
2
2
1
3
158
Jerry H. Reed, MS, RPh, FASCP, FASHP
Senior Director, Pharmacy Services
Community Health Systems
Update on Current Pharmacy Initiatives and Strategies
Pharmacy Pearls 2016CHS Pharmacy Education Series
ProCE, Inc.www.ProCE.com 79
159